REG - Tissue Regenix Group - Result of AGM

Tissue RegenixAnnouncement

23/07/2025 14:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250723:nRSW2810Sa&default-theme=true

RNS Number : 2810S  Tissue Regenix Group PLC  23 July 2025

 Tissue Regenix Group plc

('Tissue Regenix' or 'the Group')

 

Result of Annual Geneal Meeting

 

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces
that at the Annual General Meeting ('AGM') held earlier today, all resolutions
were duly passed on a show of hands.

 

The results of the proxy votes received in respect of the resolutions, given
to the Chair prior to the meeting, are set out below:

 

 Resolution            In favour   %      Against  %     Withheld
 1           Ordinary  29,848,025  99.14  259,286  0.86  11,292
 2           Ordinary  29,841,588  99.12  265,703  0.88  11,312
 3           Ordinary  29,798,308  99.12  265,907  0.88  54,388
 4           Ordinary  25,110,831  98.94  268,264  1.06  4,739,508
 5           Ordinary  29,815,967  99.11  268,125  0.89  34,511
 6           Ordinary  29,798,268  99.12  265,937  0.88  54,398
 7           Ordinary  29,818,181  99.12  265,904  0.88  34,518
 8           Ordinary  29,846,958  99.14  260,338  0.86  11,307
 9           Ordinary  29,846,728  99.13  260,576  0.87  11,299
 10          Ordinary  29,670,496  98.66  401,629  1.34  46,478
 11          Special   29,652,870  98.54  439,135  1.46  26,598
 12          Special   29,847,337  99.14  259,935  0.86  11,331

 

Notes:

1.     A "Vote withheld" is not counted in the calculation of the
percentage of shares voted "In favour" or "Against".

2.     As at 21 July 2025, being the voting deadline date in respect of
the Annual General Meeting, the total number of Ordinary Shares of 0.1p each
in issue and the total number of voting rights was 71,395,635.

 

The full text of the resolutions passed at the AGM may be found in the Notice
of AGM published on 27 June 2025.

 

For more information:

 

 Tissue Regenix Group plc                                           www.tissueregenix.com (http://www.tissueregenix.com)
 Daniel Lee, Chief Executive Officer                                via Walbrook PR

 David Cocke, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)
 Geoff Nash/Giles Balleny/Edward Whiley                             Tel: +44 (0) 20 7466 5000
 Nigel Birks - Life Science Specialist Sales
 Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)                                  Tel: +44 (0)20 7933 8780
 Alice Woodings                                                     TissueRegenix@walbrookpr.com

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that can be used
to repair diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle injuries and
wound care.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSEAFEDEISELW